Systemic Treatments for Severe Pediatric Psoriasis

Marqueling, Ann L.; Cordoro, Kelly M.

doi:10.1016/j.det.2012.12.005

Cited by 49 publications

(97 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Podobne zalecenia dotyczą stosowania kwasu salicylowego ze względu na duże ryzyko wystąpienia niepożądanych działań ubocznych. Stosowanie go u dzieci przed osiągnięciem wieku szkolnego dopuszczalne jest wyłącznie na małe powierzchnie i w stężeniu nieprzekraczającym 0,5%, zwłaszcza w przypadku niemowląt i dzieci poniżej 3. roku życia [14,[35][36][37][38][39][40][41].…”

Section: Phototherapyunclassified

“…During treatment, hepatic function and lipid levels must be monitored. The teratogenic potential of the treatment is considerably less significant in this age group [1,8,41].…”

Section: Systemic Non-biological Treatmentmentioning

confidence: 99%

“…This method is normally contraindicated in children under 12 years of age due to its adverse effects that include nausea, vomiting, hepatic toxicity, burn risk, and a longterm increase of skin cancer risk [40,41].…”

Section: Phototherapymentioning

confidence: 99%

“…None of these medications are approved by the Food and Drug Administration (FDA) for treatment of psoriasis in children due to the lack of randomized trials in this age group. Evidence of risks and benefits of the drugs is derived from their use in other conditions, such as ichthyosis and juvenile arthritis, or in patients after organ transplantations [40,41].…”

Section: Systemic Non-biological Treatmentmentioning

confidence: 99%

“…Similar caution is advised with regard to salicylic acid due to the considerable risk of adverse side-effects. In pre-school children, especially infants and children below 3 years of age, salicylic acid should only be applied on small areas and at a concentration not exceeding 0.5% [14,[35][36][37][38][39][40][41].…”

Section: Psoriasis Treatment In Childrenmentioning

confidence: 99%

See 4 more Smart Citations

Childhood psoriasis

Piekarska-Myślińska¹,

Pietrzak²,

Myśliński³

et al. 2017

View full text Add to dashboard Cite

Psoriasis is a long-lasting inflammatory skin disease with an autoimmunological and immunometabolic background. The latest European data indicate that the occurrence of psoriasis in children ranges from 0.7% to 2.1%. Despite distinct clinical characteristics, this disease continues to cause diagnostic difficulties and is often incorrectly diagnosed. The goal of this article is to present the course of psoriasis in children, basic diagnostic techniques, including dermoscopy, influence of the disease on the quality of life and risk of co-morbidity development. The therapeutic approcach to childhood psoriasis is presented. StreSzCzenieŁuszczyca jest przewlekłą chorobą zapalną skóry o podłożu autoimmunologicznym i immunometabolicznym. Według najnowszych danych europejskich zapadalność na łuszczycę u dzieci wynosi 0,7-2,1%. Pomimo charakterystycznego obrazu klinicznego schorzenie to nadal sprawia trudności diagnostyczne i bywa mylone z innymi chorobami. Celem niniejszej pracy jest omówienie odmienności przebiegu łuszczy-cy u dzieci, podstaw diagnostyki z uwzględnieniem obrazu dermatoskopowego, wpływu na jakość życia i sferę emocjonalną, zagrożenia rozwojem innych chorób, zwłaszcza dziecięcego zespołu metabolicznego oraz odmienności stosowanych metod terapeutycznych.

show abstract

Section: Phototherapyunclassified

“…During treatment, hepatic function and lipid levels must be monitored. The teratogenic potential of the treatment is considerably less significant in this age group [1,8,41].…”

Section: Systemic Non-biological Treatmentmentioning

confidence: 99%

Section: Phototherapymentioning

confidence: 99%

Section: Systemic Non-biological Treatmentmentioning

confidence: 99%

Section: Psoriasis Treatment In Childrenmentioning

confidence: 99%

See 3 more Smart Citations

Childhood psoriasis

Piekarska-Myślińska¹,

Pietrzak²,

Myśliński³

et al. 2017

View full text Add to dashboard Cite

show abstract

Pediatric Psoriasis Comorbidity Screening Guidelines

et al. 2017

Self Cite

View full text Add to dashboard Cite

IMPORTANCE-Psoriasis is a complex inflammatory skin condition associated with serious medical comorbidities in adults, including obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, and decreased quality of life. Because psoriasis begins in childhood in almost one-third of patients, early identification of risk may be critical to minimizing effects on future health. OBJECTIVE-To develop the first set of guidelines for comorbidity screening for patients with pediatric psoriasis based on current evidence. EVIDENCE REVIEW-A literature review was performed using PubMed from January 1999 through December 2015. Limiting the search to human studies published in English and removing reviews and editorials produced 153 relevant manuscripts. An expert panel in psoriasis, pediatric dermatology, pediatric rheumatology, pediatric gastroenterology, pediatric endocrinology, and adult and pediatric cardiology used the patient-centered Strength of Recommendation Taxonomy (SORT) method to evaluate and grade the quality of evidence.FINDINGS-Because of the limited number of pediatric studies published on these topics, the strength of the panel's recommendations is classified as SORT level C expert consensus recommendations. The majority of recommendations coincide with those endorsed by the American Academy of Pediatrics for the general pediatric patient but with added attention to signs Osier et al.

show abstract

Psoriasis

Seyger¹

2019

Harper's Textbook of Pediatric Dermatology

View full text Add to dashboard Cite

Systemic Treatments for Severe Pediatric Psoriasis

Cited by 49 publications

References 99 publications

Childhood psoriasis

Childhood psoriasis

Pediatric Psoriasis Comorbidity Screening Guidelines

Psoriasis

Contact Info

Product

Resources

About